Theriva Biologics, Inc. (TOVX)Healthcare | Biotechnology | Rockville, United States | NYSE American
0.26 USD
+0.00
(1.942%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.40 +0.14 (56.221%) ⇧ (April 17, 2026, 7:59 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:52 p.m. EDT
TOVX is a highly volatile stock with a low market cap and negative earnings, suggesting significant risk. The recent price movements show some momentum, but the overall trend is mixed. The stock has been trading below its 50-day average, which could indicate potential for a rebound. However, the lack of dividends and weak fundamentals make it unsuitable for long-term investment. Short-term traders might consider buying dips, but the high risk and low reliability of the forecasting model suggest caution. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.084328 |
| AutoETS | 0.086001 |
| AutoARIMA | 0.086315 |
| AutoTheta | 0.271890 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 18% |
| H-stat | 11.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 17.09 |
| Market Cap | 11,803,594 |
| Forward P/E | -1.29 |
| Beta | 0.47 |
| Previous Name | Synthetic Biologics, Inc. |
| Website | https://therivabio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8015267 |
| Address1 | 9,605 Medical Center Drive |
| Address2 | Suite 270 |
| All Time High | 262,500.0 |
| All Time Low | 0.16 |
| Ask | 0.4019 |
| Ask Size | 4,100 |
| Average Daily Volume10 Day | 13,218,830 |
| Average Daily Volume3 Month | 13,804,314 |
| Average Volume | 13,804,314 |
| Average Volume10Days | 13,218,830 |
| Beta | 0.471 |
| Bid | 0.4015 |
| Bid Size | 1,700 |
| Book Value | 0.431 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.2572 |
| Current Ratio | 1.744 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.2588 |
| Day Low | 0.2477 |
| Debt To Equity | 17.09 |
| Display Name | Theriva Biologics |
| Dividend Date | 1,534,118,400 |
| Earnings Call Timestamp End | 1,711,369,800 |
| Earnings Call Timestamp Start | 1,711,369,800 |
| Earnings Timestamp End | 1,755,174,600 |
| Earnings Timestamp Start | 1,755,174,600 |
| Ebitda | -14,912,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.092 |
| Enterprise Value | 1,376,594 |
| Eps Current Year | -0.2 |
| Eps Forward | -0.2 |
| Eps Trailing Twelve Months | -2.08 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.2068 |
| Fifty Day Average Change | 0.050400004 |
| Fifty Day Average Change Percent | 0.24371375 |
| Fifty Two Week Change Percent | -80.15267 |
| Fifty Two Week High | 1.5 |
| Fifty Two Week High Change | -1.2428 |
| Fifty Two Week High Change Percent | -0.82853335 |
| Fifty Two Week Low | 0.16 |
| Fifty Two Week Low Change | 0.097200006 |
| Fifty Two Week Low Change Percent | 0.6075001 |
| Fifty Two Week Range | 0.16 - 1.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,166,452,200,000 |
| Float Shares | 45,143,241 |
| Forward Eps | -0.2 |
| Forward P E | -1.286 |
| Free Cashflow | -5,976,500 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 15 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01633 |
| Held Percent Institutions | 0.02858 |
| Implied Shares Outstanding | 45,892,668 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.syntheticbiologics.com/investors |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,630,400 |
| Last Split Factor | 1:25 |
| Long Business Summary | Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. |
| Long Name | Theriva Biologics, Inc. |
| Market | us_market |
| Market Cap | 11,803,594 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_24424557 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-18 |
| Net Income To Common | -25,249,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 11,803,594 |
| Number Of Analyst Opinions | 2 |
| Open | 0.2564 |
| Operating Cashflow | -16,669,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 301 417 4364 |
| Post Market Change | 0.1446 |
| Post Market Change Percent | 56.22084 |
| Post Market Price | 0.4018 |
| Post Market Time | 1,776,470,398 |
| Prev Name | Synthetic Biologics, Inc. |
| Previous Close | 0.2523 |
| Price Eps Current Year | -1.286 |
| Price Hint | 4 |
| Price To Book | 0.59675175 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.687 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00490001 |
| Regular Market Change Percent | 1.94214 |
| Regular Market Day High | 0.2588 |
| Regular Market Day Low | 0.2477 |
| Regular Market Day Range | 0.2477 - 0.2588 |
| Regular Market Open | 0.2564 |
| Regular Market Previous Close | 0.2523 |
| Regular Market Price | 0.2572 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,372,334 |
| Return On Assets | -0.25513 |
| Return On Equity | -1.37817 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 45,892,668 |
| Shares Percent Shares Out | 0.1496 |
| Shares Short | 6,863,897 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 6,118,308 |
| Short Name | Theriva Biologics, Inc. |
| Short Percent Of Float | 0.1496 |
| Short Ratio | 0.44 |
| Source Interval | 15 |
| State | MD |
| Symbol | TOVX |
| Target High Price | 4.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 2.5 |
| Target Median Price | 2.5 |
| Total Cash | 13,056,000 |
| Total Cash Per Share | 0.284 |
| Total Debt | 2,629,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.08 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.30635 |
| Two Hundred Day Average Change | -0.04914999 |
| Two Hundred Day Average Change Percent | -0.16043738 |
| Type Disp | Equity |
| Volume | 1,372,334 |
| Website | https://therivabio.com |
| Zip | 20,850 |